Amgen Inc
$385.65
$5.87 (+1.55%)
$378.51Day Range$386.50
Key Statistics
Market Cap
$208.49B
Shares Outstanding
540.6M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jun 17, 1983
Round Lot
40
Locale
US
Trading Data
Day Open
$378.51
Day High
$386.50
Day Low
$378.51
Volume
8.53M
VWAP
$384.52
Prev Close
$379.78
Transactions
--
Acc. Volume
--
About Amgen Inc
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 283631,500 employeesONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA, 91320(805)447-1000IPO Jun 17, 1983US / STOCKSActiveWebsite
Identifiers
- CIK
- 0000318154
- Composite FIGI
- BBG000BBS2Y0
- Share Class FIGI
- BBG001S5NNL6
- Ticker Root
- AMGN
- SIC Code
- 2836
About Amgen Inc (AMGN) Stock
Amgen Inc (AMGN) closed the 2026-09-18 session at $385.65, up 1.55% versus the previous close (+5.87). The stock opened at $378.51 and traded between $378.51 and $386.50 during that session. Session trading volume was 8.5M shares. The volume-weighted average price (VWAP) is $384.52.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Amgen Inc has a market capitalization of $208.49 billion. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. AMGN is listed on the XNAS exchange. The company employs approximately 31,500 people. Amgen Inc is headquartered in THOUSAND OAKS, CA. The recorded listing date is 1983-06-17.
On this page you can find market AMGN stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.